ES2169087T3 - Formulaciones orales de un antifungico. - Google Patents

Formulaciones orales de un antifungico.

Info

Publication number
ES2169087T3
ES2169087T3 ES94927639T ES94927639T ES2169087T3 ES 2169087 T3 ES2169087 T3 ES 2169087T3 ES 94927639 T ES94927639 T ES 94927639T ES 94927639 T ES94927639 T ES 94927639T ES 2169087 T3 ES2169087 T3 ES 2169087T3
Authority
ES
Spain
Prior art keywords
formulations
antifungic
oral formulations
acidic
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94927639T
Other languages
English (en)
Inventor
Marc Karel Jozef Francois
Willy Maria Albert Carlo Dries
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2169087T3 publication Critical patent/ES2169087T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

LA PRESENTE INVENCION CONCIERNE UNA FORMULACION PARA LA ADMINISTRACION ORAL QUE CONSTA DE UN ANTIFUNGAL, UNA CANTIDAD SUFICIENTE DE UNA CICLODEXTRINA O DERIVADO DE LA MISMA, UN MEDIO ACIDICO ACUOSO COMO PORTADOR DE LIQUIDO DE VOLUMEN Y UN COSOLVENTE ALCOHOLICO. LA ADICION DE UNO O MAS EDULCORANTES FARMACEUTICAMENTE ACEPTABLES Y UNO O MAS SABORES PRODUCE FORMULACIONES ORALES AGRADABLES AL PALADAR. UN PROCESO PARA PREPARAR TALES FORMULACIONES Y FORMAS DE DOSIFICACION FARMACEUTICAS QUE INCLUYEN DICHAS FORMULACIONES.
ES94927639T 1993-09-30 1994-09-22 Formulaciones orales de un antifungico. Expired - Lifetime ES2169087T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12950493A 1993-09-30 1993-09-30

Publications (1)

Publication Number Publication Date
ES2169087T3 true ES2169087T3 (es) 2002-07-01

Family

ID=22440301

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94927639T Expired - Lifetime ES2169087T3 (es) 1993-09-30 1994-09-22 Formulaciones orales de un antifungico.

Country Status (31)

Country Link
US (1) US5707975A (es)
EP (1) EP0721337B1 (es)
JP (1) JP3034048B2 (es)
CN (1) CN1086579C (es)
AP (1) AP630A (es)
AT (1) ATE209916T1 (es)
AU (1) AU692180B2 (es)
CA (1) CA2170622C (es)
CY (1) CY2272B1 (es)
CZ (1) CZ288026B6 (es)
DE (1) DE69429359T2 (es)
DK (1) DK0721337T3 (es)
ES (1) ES2169087T3 (es)
FI (1) FI115443B (es)
HK (1) HK1010689A1 (es)
HU (1) HU221632B1 (es)
IL (1) IL111093A (es)
MY (1) MY111136A (es)
NO (1) NO308985B1 (es)
NZ (1) NZ273619A (es)
OA (1) OA10276A (es)
PH (1) PH31594A (es)
PL (1) PL313731A1 (es)
PT (1) PT721337E (es)
RO (1) RO115114B1 (es)
RU (1) RU2118899C1 (es)
SG (1) SG48826A1 (es)
SK (1) SK282627B6 (es)
TW (1) TW349870B (es)
WO (1) WO1995008993A1 (es)
ZA (1) ZA947619B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039761A1 (en) 1996-04-19 1997-10-30 Alpha Therapeutic Corporation A process for viral inactivation of lyophilized blood proteins
AP2000001805A0 (en) 1997-10-22 2000-06-30 Jens Ponikau Use of antifungal agents for the topical treatment of fungus-induced mucositis.
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
IL145140A0 (en) 1999-03-24 2002-06-30 Fmc Corp Improved aqueous solubility pharmaceutical formulations
MX339071B (es) 1999-03-31 2016-05-09 Janssen Pharmaceutica Nv Almidon pregelatinizado en una formulacion de liberacion controlada.
WO2001001955A1 (en) * 1999-07-02 2001-01-11 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
CA2291346A1 (en) 1999-11-26 2001-05-26 Bernard Charles Sherman Antifungal solutions
US6673373B2 (en) 2001-02-01 2004-01-06 Carlsbad Technology Inc. Antifungal formulation and the methods for manufacturing and using the same
US6806256B2 (en) 2001-03-05 2004-10-19 Ortho -Mcneil Pharmaceutical, Inc. Taste masked liquid pharmaceutical compositions
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003101392A2 (en) * 2002-05-31 2003-12-11 Transform Pharmaceuticals, Inc. Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7446107B2 (en) * 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003243699B2 (en) * 2002-06-21 2009-01-15 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
CN1255105C (zh) * 2002-12-17 2006-05-10 上海医药工业研究院 齐拉西酮及其盐的水溶性包合物及其制备方法
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
CA2440172C (en) * 2003-09-05 2011-01-11 Bernard Charles Sherman Itraconazole solution
US20050074494A1 (en) * 2003-10-06 2005-04-07 Xiu-Xiu Cheng Itraconazole immediate release formulation
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
WO2005055952A2 (en) * 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic anti-cancer compositions
GR1005154B (el) 2005-02-09 2006-03-13 Verisfield (Uk) Ltd. Σταθερες φαρμακευτικες συνθεσεις ιτρακοναζολης σευδατικο περιβαλλον
US20090118721A1 (en) * 2005-07-21 2009-05-07 Eric Bornstein Near Infrared Microbial Elimination Laser System (NIMELS)
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
TWI448285B (zh) * 2006-07-13 2014-08-11 Los Angeles Biomed Res Inst 用以治療白黴菌症（ｍｕｃｏｒｍｙｃｏｓｉｓ）及其他真菌類疾病之組合物及方法
MX2009003911A (es) 2006-12-04 2009-05-28 Supernus Pharmaceuticals Inc Formulaciones de liberacion inmediata, mejoradas de topiramato.
CA2716348C (en) 2008-02-21 2017-04-04 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome p450
US20100009009A1 (en) 2008-07-10 2010-01-14 Micropure, Inc. Method and composition for prevention and treatment of oral fungal infections
US20100233101A1 (en) 2009-02-13 2010-09-16 Micropure, Inc. Composition and method for the oxidative consumption of salivary biomolecules
SG174413A1 (en) 2009-03-19 2011-10-28 Los Angeles Biomed Res Inst Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
ES2565353T3 (es) * 2010-12-16 2016-04-04 Borje S. Andersson Formulaciones farmacéuticas de azol para administración parenteral y métodos para la preparación y el uso de las mismas como tratamiento de enfermedades sensibles a los compuestos de azol
CN102670490A (zh) * 2012-05-10 2012-09-19 南京特丰药业股份有限公司 一种伊曲康唑口服溶液及其制备方法
CN103230363A (zh) * 2013-03-29 2013-08-07 湖北凤凰白云山药业有限公司 一种抗真菌的口服溶液
CA3020197A1 (en) 2017-09-01 2019-03-01 Micropure, Inc. Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions
RU2707286C1 (ru) * 2019-07-02 2019-11-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" Фармацевтическая противогрибковая композиция на основе производного хлорфенилбутандиона и способ её получения
CN114191387A (zh) * 2021-12-26 2022-03-18 苏州海景医药科技有限公司 一种伏立康唑口服液的制备方法
CN114191386B (zh) * 2021-12-26 2024-03-12 苏州海景医药科技有限公司 一种波生坦口服溶液的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4863737A (en) * 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
US4883785A (en) * 1984-07-27 1989-11-28 Chow Wing Sun Complex of anti-fungal agent and cyclodextrin and method
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4870060A (en) * 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
CA1326995C (en) * 1988-01-29 1994-02-15 Kozo Kurihara Cyclosporin compositions
DE69330248T2 (de) * 1992-03-18 2002-03-21 Janssen Pharmaceutica Nv Itraconazol- und saperconazolstereoisomere

Also Published As

Publication number Publication date
FI961436A0 (fi) 1996-03-29
PH31594A (en) 1998-11-03
NO961233D0 (no) 1996-03-27
CZ288026B6 (cs) 2001-04-11
DK0721337T3 (da) 2002-03-25
NZ273619A (en) 1997-06-24
IL111093A (en) 2001-01-28
SK39996A3 (en) 1996-12-04
HU221632B1 (hu) 2002-12-28
IL111093A0 (en) 1994-11-28
DE69429359T2 (de) 2002-07-25
PL313731A1 (en) 1996-07-22
DE69429359D1 (de) 2002-01-17
TW349870B (en) 1999-01-11
SG48826A1 (en) 1998-05-18
AU692180B2 (en) 1998-06-04
RO115114B1 (ro) 1999-11-30
CZ82396A3 (en) 1996-06-12
PT721337E (pt) 2002-05-31
AP630A (en) 1998-03-10
ATE209916T1 (de) 2001-12-15
NO308985B1 (no) 2000-11-27
SK282627B6 (sk) 2002-10-08
ZA947619B (en) 1996-03-29
CY2272B1 (en) 2003-07-04
HK1010689A1 (en) 1999-06-25
CN1136776A (zh) 1996-11-27
FI961436A (fi) 1996-03-29
CN1086579C (zh) 2002-06-26
CA2170622A1 (en) 1995-04-06
OA10276A (en) 1997-10-07
FI115443B (fi) 2005-05-13
US5707975A (en) 1998-01-13
AP9600792A0 (en) 1996-04-30
EP0721337B1 (en) 2001-12-05
AU7697994A (en) 1995-04-18
CA2170622C (en) 1999-07-27
WO1995008993A1 (en) 1995-04-06
JPH09502989A (ja) 1997-03-25
EP0721337A1 (en) 1996-07-17
HUT74378A (en) 1996-12-30
MY111136A (en) 1999-08-30
RU2118899C1 (ru) 1998-09-20
NO961233L (no) 1996-03-27
JP3034048B2 (ja) 2000-04-17
HU9600804D0 (en) 1996-05-28

Similar Documents

Publication Publication Date Title
ES2169087T3 (es) Formulaciones orales de un antifungico.
HUP0302131A2 (hu) Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
HK1096034A1 (en) A solid dosage form comprising a fibrate
ECSP083351A (es) Composiciones farmacéuticas
AR057180A1 (es) Formulacion farmaceutica de absorcion oral que comprende insulina, entre otros, y su metodo de administracion
HK1100480A1 (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
CR7362A (es) Formulaciones farmaceuticas de derivado de platino
PT1207756E (pt) Utilizacao de espinosade ou de uma formulacao que compreende espinosade
WO2007047371A3 (en) Pharmaceutical packaging of an oral dosage combination
DE69923336D1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
FI955136A0 (fi) Gamma-interferonin stabiilit, nestemäiset koostumukset
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
DE60124144D1 (de) Pharmazeutische zusammenstellungen zur verstärkung der artzneimitteleffekte
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
WO2002020056A3 (en) Methods and compositions for producing a neurosalutary effect in a subject
ITTO20050301A1 (it) Formulazioni liquide orali contenenti citalopram
ECSP045039A (es) Composiciones de disgregación intraoral organolepticamente aceptables

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 721337

Country of ref document: ES